Dr. Reddy's Laboratories Limited
All news and filings related to Dr. Reddy's Laboratories Limited.
View all news & filings- Low impact
Dr. Reddy's Laboratories Notifies Loss of Share Certificates
Dr. Reddy's Laboratories Limited announced the loss of share certificates. Shareholders or claimants have applied for duplicates. A 15-day window is open for claims at the Hyderabad office before duplicates are issued. The notice was published on September 16, 2026.
Read the summary - Medium impact
Dr. Reddy's Mexico API Facility Receives Two Observations from USFDA
Dr. Reddy's Mexico API facility received two observations from the USFDA after a records assessment conducted between July 17, 2026, and September 8, 2026. The company will respond to the observations within the stipulated timeline.
Read the summary - Low impact
Dr. Reddy's Allots 375 Shares Under ESOPs on Sep 10, 2026
Dr. Reddy's Laboratories allotted 375 equity shares on September 10, 2026, under its ESOP scheme. The shares were exercised at Re.1/- each. Post-allotment, total issued shares are 83,46,81,285, with a total issued share capital of Rs. 83,46,81,285.
Read the summary - Low impact
Dr. Reddy's to Participate in Investor Meetings on Sept 17 & 24, 2026
Dr. Reddy's Laboratories will participate in investor meetings organized by ICICI Securities on September 17, 2026 (in-person) and Bank of America on September 24, 2026 (virtual). Management will engage with institutional investors during these scheduled events.
Read the summary - Low impact
Dr. Reddy's Allots 4,110 Equity Shares Under ESOP Scheme
Dr. Reddy's Laboratories allotted 4,110 equity shares on August 26, 2026, to employees who exercised stock options under its ESOP Scheme, 2002. The allotment brings the total issued shares to 83,46,80,910, with a total share capital of ₹83,46,80,910.
Read the summary - Low impact
Dr. Reddy's Laboratories: Public Notice Regarding Lost Share Certificates
Dr. Reddy's Laboratories Limited issued a public notice on August 20, 2026, regarding lost share certificates. Shareholders who have lost certificates must inform the company within 15 days to receive duplicates. The notice details shareholder names and certificate information.
Read the summary - Medium impact
Dr. Reddy's Bachupally Facility Receives 4 Observations in USFDA GMP Inspection
Dr. Reddy's Bachupally manufacturing facility underwent a USFDA GMP inspection from August 6-14, 2026. The inspection resulted in a Form 483 with four observations, which the company plans to address within the given timeline.
Read the summary - Medium impact
Dr. Reddy's API facility inspection closed with Voluntary Action Indicated (VAI) by USFDA
Dr. Reddy's Laboratories Limited announced that the USFDA inspection at its Mirfield API manufacturing facility has concluded with a 'Voluntary Action Indicated (VAI)' classification. The inspection is now officially closed by the USFDA.
Read the summary - Medium impact
Dr. Reddy's Terminates Distribution Agreement with Novartis India
Dr. Reddy's Laboratories has terminated its distribution agreement with Novartis India Limited, effective from September 30, 2026. This follows a change in NIL's controlling shareholding. The company will continue to commercialize the brands until the termination date.
Read the summary - High impact
Dr. Reddy's Rituximab Biosimilar Approved by US FDA
Dr. Reddy's Laboratories received U.S. FDA approval for its rituximab biosimilar on August 1, 2026. The product, developed and manufactured by Dr. Reddy's, will be exclusively commercialized in the U.S. by Fresenius Kabi. This approval strengthens Dr. Reddy's biosimilars portfolio.
Read the summary - Medium impact
Dr. Reddy's Srikakulam Unit Receives 3 Observations from USFDA Inspection
Dr. Reddy's Srikakulam facility underwent a USFDA PAI and GMP inspection from July 20-29, 2026. The inspection resulted in three observations noted on a Form 483. The company confirmed it will address these observations within the required timeframe.
Read the summary - Low impact
Dr. Reddy's Antibiotic Drug Receives Thailand Approval; No Material Impact
Dr. Reddy's Laboratories confirmed its antibiotic drug NUZOLVENCE® (zoliflodacin) received Thailand approval, six months after US authorization. The company stated no negotiations were ongoing and believes the news has no material impact.
Read the summary - Medium impact
Dr. Reddy's Q1FY27 Earnings Call Transcript Released; Revenue Declines 5.6%
Dr. Reddy's Q1FY27 consolidated revenue declined 5.6% YoY to ₹8,071 crores, impacted by lower lenalidomide sales and a ₹240 crore provision for semaglutide API issues. Underlying base business showed double-digit growth. EBITDA margin was 12.5%, expected to improve with semaglutide resumptions in November 2026.
Read the summary - Medium impact
Dr. Reddy's Laboratories Appoints New Independent Director and Statutory Auditors at AGM
Dr. Reddy's Laboratories' AGM approved re-appointment of Dr. K P Krishnan as Independent Director (Jan 7, 2027 - Jan 6, 2032). Mr. Srikanth Velamakanni was appointed as Independent Director (Jul 1, 2026 - Jun 30, 2031). Deloitte Haskins & Sells, LLP appointed as Statutory Auditors for five years.
Read the summary - Medium impact
Dr. Reddy's Approves Re-appointment of Director, Appoints New Director & Auditor at AGM
Dr. Reddy's AGM on July 23, 2026, saw members approve Dr. K P Krishnan's re-appointment as Independent Director (Jan 7, 2027 - Jan 6, 2032) and Mr. Srikanth Velamakanni's appointment (Jul 1, 2026 - Jun 30, 2031). Deloitte Haskins & Sells, LLP appointed as Statutory Auditors for five years.
Read the summary - Medium impact
Dr. Reddy's 42nd AGM Concludes: All Resolutions Passed, Final Dividend Declared
Dr. Reddy's Laboratories Limited held its 42nd AGM on July 23, 2026. All resolutions passed, including the adoption of FY26 financial statements and declaration of an ₹8 final dividend per share. Key appointments and auditor re-appointments were confirmed.
Read the summary - Low impact
Dr. Reddy's Laboratories: Newspaper publication of unaudited financial results for Q1 FY27
Dr. Reddy's Laboratories Limited announced its unaudited financial results for the quarter ended June 30, 2026. The results were published in newspapers on July 23, 2026, in compliance with SEBI regulations.
Read the summary - Low impact
Dr. Reddy's Laboratories Q1 FY27 Earnings Call Audio Recordings Released
Dr. Reddy's Laboratories released audio recordings of its earnings call held on July 22, 2026, for the quarter ended June 30, 2026. The link to the recordings has been provided.
Read the summary - Low impact
Dr. Reddy's Grants 15,933 Stock Options Under ESOP Scheme 2018
Dr. Reddy's Laboratories granted 15,933 stock options to employees under its 2018 ESOP scheme. The exercise price is ₹1,206 per option. Vesting is 100% after three years. The grant was approved on July 22, 2026.
Read the summary - Medium impact
Dr. Reddy's Appoints Dr. Sridevi Khambhampaty as Global Head of Biologics
Dr. Reddy's Laboratories appointed Dr. Sridevi Khambhampaty as Global Head of Biologics and Senior Management Personnel, effective July 22, 2026. The company also appointed Deloitte Haskins & Sells, LLP as its Independent Registered Public Accounting Firm.
Read the summary - High impact
Dr. Reddy's Q1FY27 Revenue Down 6% YoY to ₹80,705 Crore, Appoints Dr. Sridevi Khambhampaty
Dr. Reddy's Q1FY27 consolidated revenues were ₹80,705 million (₹8,070.5 crore), down 5.6% YoY. Profit after tax attributable to equity holders was ₹4,435 million (₹443.5 crore). Dr. Sridevi Khambhampaty appointed Global Head of Biologics. Deloitte Haskins & Sells appointed as Independent Registered Public Accounting Firm. Results impacted by lower lenalidomide sales and semaglutide API issue.
Read the summary - Medium impact
Dr. Reddy's faces Semaglutide supply halt due to impurity; resumes by Oct/Nov
Dr. Reddy's halts Semaglutide injection supply due to an impurity found during scale-up. Resumption expected by late Oct/early Nov 2026, targeting 6-7 million pens for Q3/Q4 FY27. Investigation and validation to conclude by September. No patient safety impact or recall necessary.
Read the summary - Medium impact
Dr. Reddy's to announce Q1FY27 results on July 22, 2026; Earnings call at 7:30 PM IST
Dr. Reddy's Laboratories will announce its Q1FY27 results on July 22, 2026. The company will host an earnings call on the same day at 7:30 PM IST to discuss financial performance. Presentation and transcript will be available on the company website.
Read the summary - Low impact
Dr. Reddy's Releases Audio Recording of July 9, 2026 Conference Call
Dr. Reddy's Laboratories has made available the audio recording of its conference call held on July 9, 2026. The recording can be accessed via a provided weblink, fulfilling regulatory disclosure requirements.
Read the summary - Medium impact
Dr. Reddy's Semaglutide Supply Delayed Due to API Issue; Concall Today
Dr. Reddy's is delaying semaglutide supplies due to an API issue impacting product quality. Patient safety and regulatory filings are unaffected. A concall is scheduled for July 9, 2026, at 16:30 IST to discuss the issue.
Read the summary - Medium impact
Dr. Reddy's Semaglutide Batches Out of Spec; Company to Host Concall
Dr. Reddy's reported semaglutide batches out of specification due to API issues. Commercial supplies are delayed, but patient safety is unaffected. A conference call is scheduled for July 9, 2026, at 16:30 IST to discuss the matter.
Read the summary - Low impact
Dr. Reddy's Laboratories: Certificate of Dematerialisation for Q1 FY27
Dr. Reddy's Laboratories received a certificate for Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. This covers the quarter ended June 30, 2026. The certificate confirms dematerialisation processing of securities by the Registrar and Share Transfer Agent, Bigshare Services.
Read the summary - Low impact
Dr. Reddy's Board Meeting on July 22 to Consider Q1 FY27 Financial Results; Trading Window Closed
Dr. Reddy's Board meeting on July 22, 2026, to approve Q1 FY27 standalone and consolidated financial results. Trading window for securities will be closed from June 24, 2026, to July 24, 2026.
Read the summary - Medium impact
Dr. Reddy's Laboratories Announces 42nd AGM on July 23, 2026, Recommends Final Dividend
Dr. Reddy's Laboratories will hold its 42nd AGM on July 23, 2026. The company recommended a final dividend of ₹8 per equity share for FY2025-26. July 10, 2026, is the record date, and the dividend will be paid by July 30, 2026.
Read the summary - Low impact
Dr. Reddy's Allots 6,730 Equity Shares Under ESOPs
Dr. Reddy's Laboratories Limited allotted 6,730 equity shares on June 19, 2026, under its ESOP schemes. This issuance increases the total issued shares to 83,46,76,800, with a total issued share capital of Rs. 83,46,76,800/-.
Read the summary - Medium impact
Dr. Reddy's Launches Generic Bosutinib 400mg in US, First-to-Market
Dr. Reddy's launched Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the US on June 13, 2026. This marks a first-to-market entry and secures 180 days of exclusivity. The Bosulif® brand had US sales of approximately $253.8 million for the 12 months ended April 2026.
Read the summary - Low impact
Dr. Reddy's to Participate in Investec Investor Meet in London on June 16-17, 2026
Dr. Reddy's Laboratories Limited will attend an investor conference in London organized by Investec from June 16-17, 2026. Management will participate in in-person group meetings with institutional investors, scheduled from 09:00 to 17:00 BST.
Read the summary - Low impact
Dr. Reddy's to Participate in Investor Meetings on June 9 & 10, 2026
Dr. Reddy's Laboratories will attend investor meetings on June 9 and June 10, 2026. The meetings are organized by ICICI Securities in Mumbai and Macquarie in Hyderabad, respectively. These will be in-person group meetings.
Read the summary - Low impact
Dr. Reddy's Laboratories to Participate in Bank of America Investor Meet on June 5
Dr. Reddy's Laboratories will attend an investor conference organized by Bank of America in Hyderabad on June 5, 2026. The in-person group meeting is scheduled from 08:00 to 09:00 IST.
Read the summary - Low impact
Dr. Reddy's Files Annual Report 20-F for Fiscal Year Ended March 31, 2026
Dr. Reddy's Laboratories filed its annual consolidated financial statements for the fiscal year ended March 31, 2026, in Form 20-F with the US SEC on May 30, 2026. The report is prepared under IFRS and is available on the company's website.
Read the summary - Low impact
Dr. Reddy's to Ring NYSE Closing Bell for 25th Listing Anniversary
Dr. Reddy's Laboratories will ring the Closing Bell at the New York Stock Exchange on May 29, 2026, celebrating 25 years of its NYSE listing. The ceremony marks a significant milestone since its debut in April 2001.
Read the summary - Low impact
Dr. Reddy's: Newspaper notice on unclaimed dividend and shares transfer to IEPF
Dr. Reddy's Laboratories is transferring unclaimed dividends and shares to the IEPF by August 30, 2026. Shareholders with unpaid dividends from FY 2018-19 onwards are urged to claim by this date. The notice is published in Business Standard and Nava Telangana.
Read the summary - Low impact
Dr. Reddy's Laboratories Releases Q4FY26 Earnings Call Transcript
Dr. Reddy's Laboratories released the transcript of its Q4FY26 earnings call held on May 12, 2026. The call discussed financial results for the quarter and fiscal year ended March 31, 2026. The transcript is available on the company's website.
Read the summary - Medium impact
Dr. Reddy's Launches Generic Semaglutide Injection in Canada
Dr. Reddy's Laboratories launched its generic Semaglutide Injection in Canada on May 15, 2026, after receiving Health Canada approval on April 28, 2026. Canada is the first G7 country to authorize this generic. The injection is for type 2 diabetes treatment.
Read the summary - Low impact
Dr. Reddy's Laboratories Approves Audited Financial Results for Q4FY26 and FY26
Dr. Reddy's Laboratories Board approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The results were published on May 13, 2026, in Business Standard and Andhra Prabha newspapers.
Read the summary - Low impact
Dr. Reddy's Laboratories Releases Audio Recording of Q4 FY26 Earnings Call
Dr. Reddy's Laboratories released the audio recording of its earnings call for the quarter ended March 31, 2026. The call took place on May 12, 2026. The recording is accessible via a provided web link.
Read the summary - High impact
Dr. Reddy's Q4FY26 Revenues at ₹7,516 Cr, PAT at ₹220 Cr
Dr. Reddy's reported Q4FY26 revenues of ₹7,516 crore, a 12% YoY increase, with PAT at ₹220 crore. FY26 revenues stood at ₹33,593 crore, up 3% YoY. The company launched generic semaglutide in Canada and India, and acquired Progynova® brands in India. It also received a Gold Medal from EcoVadis.
Read the summary - Medium impact
Dr. Reddy's Board Approves Key Re-appointments and Appointments, Elevates Sandeep Khandelwal
Dr. Reddy's Board approved re-appointment of Dr. K P Krishnan as Independent Director (Jan 2027-Jan 2032) and appointment of Mr. Srikanth Velamakanni as Independent Director (Jul 2026-Jun 2031). Deloitte Haskins & Sells LLP appointed as Statutory Auditors for five years. Mr. Sandeep Khandelwal elevated to Senior Management.
Read the summary - Medium impact
Dr. Reddy's Board Approves Director Re-appointments, New Auditor, and Senior Management Elevation
Dr. Reddy's Board re-appointed Dr. K P Krishnan as Independent Director (Jan 2027-Jan 2032) and appointed Mr. Srikanth Velamakanni as Independent Director (Jul 2026-Jun 2031), subject to shareholder approval. Deloitte Haskins & Sells appointed as Statutory Auditors for five years. Mr. Sandeep Khandelwal elevated to Senior Management Personnel.
Read the summary - Medium impact
Dr. Reddy's Board Approves Key Appointments and Auditor Changes.
Dr. Reddy's Board re-appointed Dr. K P Krishnan as Independent Director (Jan 7, 2027 - Jan 6, 2032) and appointed Mr. Srikanth Velamakanni as Independent Director (July 1, 2026 - June 30, 2031). Deloitte Haskins & Sells LLP appointed as Statutory Auditors for five years. Mr. Sandeep Khandelwal elevated to Senior Management.
Read the summary - Medium impact
Dr. Reddy's Board Approves Audited FY26 Results, Recommends ₹8 Dividend, Appoints New Directors
Dr. Reddy's Board approved audited FY26 results, with Q4 revenues at ₹75,162 million and FY26 revenues at ₹335,933 million. A final dividend of ₹8 per share was recommended. The company approved the AGM on July 23, 2026, and re-appointed Dr. K P Krishnan and appointed Mr. Srikanth Velamakanni as Independent Directors.
Read the summary - Medium impact
Dr. Reddy's Board Approves Audited FY26 Results, Recommends Final Dividend of ₹8 Per Share
Dr. Reddy's Laboratories announced its audited financial results for FY26. The company recommended a final dividend of ₹8 per share. The 42nd AGM will be held on July 23, 2026. Key appointments and re-appointments were also approved.
Read the summary - Medium impact
Dr. Reddy's Board Approves FY26 Results, Recommends ₹8 Dividend, Appoints New Directors
Dr. Reddy's Board approved FY26 audited results, reporting Q4FY26 revenues of ₹75,162 million and FY26 revenues of ₹335,933 million. A final dividend of ₹8 per share was recommended. Key appointments include Dr. K P Krishnan (re-appointment) and Mr. Srikanth Velamakanni (appointment) as Independent Directors.
Read the summary - Low impact
Dr. Reddy's Laboratories to Participate in Investor Meetings in May 2026
Dr. Reddy's Laboratories will participate in investor meetings in May 2026. Management will attend a group meet organized by HSBC in Mumbai on May 14-15, 2026, and another by Bank of America in Singapore from May 18-19, 2026. These meetings aim to update investors on the company's business.
Read the summary - Low impact
Dr. Reddy's Approves Grant of Over 11.9 Lakh Stock Options
Dr. Reddy's Laboratories approved the grant of 8,16,119 Indian Stock Options and 3,76,115 ADR Stock Options to employees. The exercise price for all options is ₹1,293.90. Options vest fully after 3 years.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio - Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio - Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio - Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio